Abstract:Background: Hepatocellular carcinoma (HCC) ranks prominently in cancer-related mortality globally. Surgery remains the main therapeutic option for the treatment of HCC, but high post-operative recurrence rate makes prognostic prediction challenging. The quest for a reliable model to predict HCC recurrence continues to enhance prognosis. We aim to develop a nomogram with multiple factors to accurately estimate the risk of post-operative recurrence in patients with HCC. Methods: A single-center retrospective study on 262 patients who underwent partial hepatectomy for HCC at the Eastern Hepatobiliary Surgery Hospital from May 2010 to April 2013 was conducted where immunohistochemistry assessed Yes-associated protein (YAP) expression in HCC. In the training cohort, a nomogram that incorporated YAP expression and clinicopathological features was constructed to predict 2-, 3-, and 5-year recurrence-free survival (RFS). The performance of the nomogram was assessed with respect to discrimination calibration, and clinical usefulness with external validation. Results: A total of 262 patients who underwent partial hepatectomy for HCC at the Eastern Hepatobiliary Surgery Hospital were included in our study. HCC patients with high YAP expression exhibited significantly higher recurrence and reduced overall survival (OS) rates compared to those with low YAP expression (P<0.001). YAP was significantly associated with alpha-fetoprotein (AFP) (P=0.03), microvascular invasion (MVI) (P<0.001), and tumor differentiation grade (P<0.001). In the training cohort, factors like YAP expression, hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA), Child-Pugh stage, tumor size, MVI, and tumor differentiation were identified as key elements for the predictive model. Two YAP-centric Nomograms were developed, with one focused on predicting postoperative OS and the other on RFS. The calibration curve further confirmed the model's accuracy in the training cohort. The validation cohort confirmed the model's predictive accuracy. Conclusions: The proposed nomogram combining the YAP, a predictor of HCC progression, and clinical features achieved more-accurate prognostic prediction for patients with HCC after partial hepatectomy, which may help clinicians implement more appropriate interventions.

Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma

Yap Promotes The Proliferation Of Neuroblastoma Cells Through Decreasing The Nuclear Location Of P27(Kip1) Mediated By Akt

Interleukin-6 Induced by YAP in Hepatocellular Carcinoma Cells Recruits Tumor-Associated Macrophages

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients

Relationship between Yes-Associated Protein 1 and Prognosis of Digestive System Neoplasm: Quantitative Analysis and Bioinformatics Analysis Based on 4023 Patients

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Expression of Yes-associated protein in gastric adenocarcinoma and its clinical significance

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma

The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness

The Dual Functions of YAP-1 to Promote and Inhibit Cell Growth in Human Malignancy.

Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients

The role of YAP1 in liver cancer stem cells: proven and potential mechanisms

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Overexpression of Yes-associated Protein Confers Doxorubicin Resistance in Hepatocellullar Carcinoma.

Abstract PO3-28-06: YAP1 expression is a good prognostic marker of hormone receptor-positive HER2-negative breast cancer: clinicopathologic analysis using the 21-gene recurrent score

Yes-Associated Protein in Hepatocellular Carcinoma is Associated with Tumor Differentiation and Patient Age at Diagnosis, but Not Markers of Hbv Infection

Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer

Differences in Yes-associated Protein and Mrna Levels in Regenerating Liver and Hepatocellular Carcinoma

YAP-based nomogram predicts poor prognosis in patients with hepatocellular carcinoma after curative surgery

Clinical Significance of Yes-associated Protein 1 in Esophageal Squamous Cell Carcinoma